Soleno Therapeutics (Nasdaq:SLNO) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

SLNO Overzicht aandelen

Soleno Therapeutics, Inc., een biofarmaceutisch bedrijf in een klinische fase, richt zich op de ontwikkeling en commercialisering van nieuwe geneesmiddelen voor de behandeling van zeldzame ziekten.

Over het bedrijf

SLNO fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	5/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

Verhandeld tegen 83.4% onder onze schatting van de reële waarde

De winst zal naar verwachting met 68.16% per jaar groeien

Analisten zijn het erover eens dat de aandelenkoers met 45.8% zal stijgen

Risicoanalyse

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

Aanzienlijke insider-verkoop in de afgelopen 3 maanden

Soleno Therapeutics, Inc. Concurrenten

Akero Therapeutics

NasdaqGS:AKRO

US$1.9b

Mirum Pharmaceuticals

NasdaqGM:MIRM

US$1.9b

Beam Therapeutics

NasdaqGS:BEAM

US$1.9b

Fusion Pharmaceuticals

NasdaqGS:FUSN

US$1.8b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Soleno Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	US$49.63
52 Week Hoogtepunt	US$55.56
52 Week Laag	US$21.30
Bèta	-1.45
11 maand verandering	2.25%
3 maanden verandering	17.02%
1 Jaar Verandering	113.19%
33 jaar verandering	293.70%
5 jaar verandering	104.87%
Verandering sinds IPO	-83.50%

Recent nieuws en updates

Recent updates

We're Not Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn

Mar 08

Here's Why We're Watching Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation

Sep 20

Soleno sheds 13% as 1-for-15 reverse stock split takes effect

Aug 26

Companies Like Soleno Therapeutics (NASDAQ:SLNO) Could Be Quite Risky

Aug 12

Soleno Therapeutics surges 49% on regulatory pathway for Prader-Willi syndrome treatment

Jul 20

Here's Why Soleno Therapeutics (NASDAQ:SLNO) Must Use Its Cash Wisely

May 10

We're A Little Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Rate

Jan 24

Soleno shares soar on FDA Orphan Drug status for Glycogen Storage Disease treatment

Jun 02

Will Soleno Therapeutics (NASDAQ:SLNO) Spend Its Cash Wisely?

Mar 23

Need To Know: Soleno Therapeutics, Inc. (NASDAQ:SLNO) Insiders Have Been Buying Shares

Jan 29

Soleno Therapeutics: Could Be Big Fish In The Small Pond

Jan 08

Here's Why We're Not Too Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation

Dec 07

Rendement voor aandeelhouders

	SLNO	US Biotechs	US Markt
7D	1.0%	-0.5%	0.3%
1Y	113.2%	18.0%	32.4%

Rendement versus industrie: SLNO overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 22.1 % opleverde.

Rendement versus markt: SLNO overtrof de US markt, die het afgelopen jaar een rendement opleverde van 34.1 %.

Prijsvolatiliteit

Is SLNO's price volatile compared to industry and market?
SLNO volatility
SLNO Average Weekly Movement	8.0%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: SLNO heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 8% ) van SLNO is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1999	33	Anish Bhatnagar	soleno.life

Soleno Therapeutics, Inc., een biofarmaceutisch bedrijf in een klinische fase, richt zich op de ontwikkeling en commercialisering van nieuwe geneesmiddelen voor de behandeling van zeldzame ziekten. De belangrijkste kandidaat is Diazoxide Choline Extended-Release tabletten, een eenmaal daags oraal tablet, dat zich in Fase III van het klinisch onderzoek bevindt voor de behandeling van het Prader-Willi Syndroom. Het bedrijf was voorheen bekend als Capnia, Inc. en veranderde zijn naam in Soleno Therapeutics, Inc. in mei 2017.

Soleno Therapeutics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Soleno Therapeutics zich tot de beurswaarde?
SLNO fundamentele statistieken
Marktkapitalisatie	US$1.93b
Inkomsten(TTM)	-US$65.41m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-29.5x

Koers/Winstverhouding

Is SLNO overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
SLNO resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$65.41m
Inkomsten	-US$65.41m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.68
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde SLNO op de lange termijn?

Bekijk historische prestaties en vergelijking

SLNO Overzicht aandelen

Beloningen

Risicoanalyse

Soleno Therapeutics, Inc. Concurrenten

NasdaqGS:AKRO

US$1.9b

NasdaqGM:MIRM

US$1.9b

NasdaqGS:BEAM

US$1.9b

NasdaqGS:FUSN

US$1.8b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

President recently sold US$5.5m worth of stock

Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

Soleno Therapeutics, Inc. Announces Board Changes

No longer forecast to breakeven

President recently sold US$5.8m worth of stock

Soleno Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Recent updates

President recently sold US$5.5m worth of stock

Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

Soleno Therapeutics, Inc. Announces Board Changes

No longer forecast to breakeven

President recently sold US$5.8m worth of stock

Soleno Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

President recently sold US$800k worth of stock

Soleno Therapeutics, Inc Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome

Independent Chairman exercised options to buy US$2.6m worth of stock.

Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024

Soleno Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $138 million.

Soleno Therapeutics, Inc. Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)

Soleno Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

President recently sold US$785k worth of stock

We're Not Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn

Price target increased by 19% to US$60.17

Soleno Therapeutics Strengthens Leadership Team with Key Appointments

Forecast to breakeven in 2026

Vice President of Clinical Operations notifies of intention to sell stock

President recently sold US$3.3m worth of stock

President notifies of intention to sell stock

President recently sold US$1.5m worth of stock

Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Long-Term Open Label Study of DCCR in Prader-Willi Syndrome

Price target increased by 23% to US$45.67

Soleno Therapeutics, Inc. announced that it has received $59.98825 million in funding

New major risk - Shareholder dilution

Soleno Therapeutics, Inc. announced that it expects to receive $30 million in funding

Soleno Therapeutics, Inc. Announces Positive Statistically Significant Top-Line Results from Randomized Withdrawal Period of Study C602 of Dccr for Prader-Willi Syndrome

Here's Why We're Watching Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation

Soleno Therapeutics Appoints Matthew Pauls to Board of Directors

New major risk - Financial position

No longer forecast to breakeven

No longer forecast to breakeven

Soleno Therapeutics, Inc. announced that it has received $10.000044 million in funding from Abingworth LLP, Vivo Capital, LLC, Nantahala Capital Management, LLC, Brightleaf Capital, Corbin Capital Partners, L.P.

Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome

Soleno Therapeutics, Inc. Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome

Forecast to breakeven in 2025

Soleno Therapeutics, Inc. announced that it expects to receive $59.89 million in funding from Abingworth LLP, Vivo Capital, LLC, Nantahala Capital Management, LLC, Brightleaf Capital, Corbin Capital Partners, L.P.

Price target decreased to US$9.00

Insufficient new directors

Soleno Therapeutics, Inc. Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome

Soleno sheds 13% as 1-for-15 reverse stock split takes effect

Companies Like Soleno Therapeutics (NASDAQ:SLNO) Could Be Quite Risky

Insufficient new directors

Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics surges 49% on regulatory pathway for Prader-Willi syndrome treatment

Insufficient new directors

Here's Why Soleno Therapeutics (NASDAQ:SLNO) Must Use Its Cash Wisely

Price target decreased to US$5.00

Soleno Therapeutics, Inc., Annual General Meeting, Jun 01, 2022

Soleno Therapeutics Provides Regulatory Update on Dccr for the Treatment of Prader-Willi Syndrome

We're A Little Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Rate

Soleno Therapeutics Announces Positive Data Showing Continued Significant Improvements in Symptoms of Pws Following One Year Treatment with Dccr

Soleno Therapeutics, Inc.(NasdaqCM:SLNO) dropped from Russell 3000E Growth Index

Soleno Therapeutics Receives Orphan Drug Designation from FDA for Diazoxide Choline for the Treatment of Glycogen Storage Disease Type 1A

Soleno shares soar on FDA Orphan Drug status for Glycogen Storage Disease treatment

Soleno Therapeutics Announces Presentation of Positive Behavioral Data from Ongoing Extension Study of DCCR for Treatment of Prader-Willi Syndrome

Will Soleno Therapeutics (NASDAQ:SLNO) Spend Its Cash Wisely?

Soleno Therapeutics, Inc. Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome